查看静脉注射脂质体包封的胞壁酰三肽治疗狗骨肉瘤的源代码

原文：https://pubmed.ncbi.nlm.nih.gov/2733037/

Published: 1989

== Abstract ==

犬骨肉瘤 (osteosarcoma) 是狗的一种自发性恶性肿瘤，其特征是在'''诊断时微转移至肺和肺外组织'''。标准治疗包括'''截肢'''，但中位生存时间为 3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。

Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.

<br>

== Introduction ==

<br>

== Reference ==

* 2000: [[犬血管肉瘤的治疗：2000 年及以后]]兽医内科杂志 [https://pubmed.ncbi.nlm.nih.gov/11012108/ Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine 2000]
* 2010: [[狗的胸腔镜次全心包切除术和右心房肿块切除术]] [https://pubmed.ncbi.nlm.nih.gov/20807133/ Thoracoscopic subtotal pericardiectomy and right atrial mass resection in a dog]
* 2013: [[狗狗原发性心脏血管肉瘤的流行病学、临床和病理特征：51例的回顾]]。兽医学杂志 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942993/ Epidemiological, clinical and pathological features of primary cardiac hemangiosarcoma in dogs: a review of 51 cases.] 
* 2014: [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤] [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs] 
* 2014: [[基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估]] [https://pubmed.ncbi.nlm.nih.gov/24697499/ A retrospective evaluation of doxorubicin-based chemotherapy for dogs with right atrial masses and pericardial effusion]
* 2017: [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较] [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA] 
* 2018: [[犬内脏血管肉瘤单独手术治疗或手术加多柔比星治疗：37例（2005-2014年）]] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091137/ Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014)]


* [https://todaysveterinarypractice.com/nutrition/nutritional-management-of-veterinary-patients-with-neoplasia/ Nutritional Management of Patients with Neoplasia] [[小动物肿瘤患者的营养管理]]
* [[狗狗心包积液]]

<br>